Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study
Mark S. Pearson, Bemnet Tedla, Gebeyaw Getnet Mekonnen, Carla Proietti, Luke Becker, Rie Nakajima, Al Jasinskas, Denise L. Doolan, Abena S. Amoah, Stefanie Knopp, David Rollinson, Said M. Ali, Fatma Kabole, Cornelis H. Hokke, Akim A Adegnika, Matthew A. Field, Govert J. van Dam, Paul L. A. M. Corstjens, Takafira Mduluza, Francisca Mutapi, Claude Oeuvray, Béatrice Gréco, Sujittra Chaiyadet, Thewarach Laha, Pengfei Cai, Donald P. McManus, María Elena Bottazzi, Philip L. Felgner, Javier Sotillo, Alex Loukas
Abstract
BACKGROUND: secretome to find antibody biomarkers of schistosome infection, validate their diagnostic performance in samples from endemic populations, and evaluate their utility as point of care immunochromatographic tests (POC-ICTs) to diagnose urogenital schistosomiasis in the field. METHODS: infection from serum in a field-deployable format. FINDINGS: -TSP-2 showed absolute specificity and a sensitivity of 75% and MS3_01370 showed absolute specificity and a sensitivity of 89%. INTERPRETATION: -TSP-2 and MS3_01370, could be used as sensitive, specific, and field-deployable diagnostics to support schistosomiasis control and elimination initiatives, with particular focus on post-elimination surveillance. FUNDING: Australian Trade and Investment Commission and Merck Global Health Institute.